<?xml version="1.0" encoding="UTF-8"?>
<p id="para90">The nucleoside analogue gemcitabine is not effluxed by the multidrug resistance gene-1–P glycoprotein (MDR-1–Pgp), which is overexpressed in some peripheral T-cell lymphomas
 <xref rid="bib7" ref-type="bibr">7</xref>, 
 <xref rid="bib8" ref-type="bibr">8</xref> on the tumour cells, residual lymphocytes, or in the endothelium
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> and has shown activity both as monotherapy
 <xref rid="bib9" ref-type="bibr">9</xref>, 
 <xref rid="bib10" ref-type="bibr">10</xref>, 
 <xref rid="bib11" ref-type="bibr">11</xref> and in combination with platinum and steroids
 <xref rid="bib12" ref-type="bibr">12</xref>, 
 <xref rid="bib13" ref-type="bibr">13</xref>, 
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib17" ref-type="bibr">17</xref>, 
 <xref rid="bib18" ref-type="bibr">18</xref>, 
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref> in patients with relapsed or refractory peripheral T-cell lymphoma. The regimen of intravenous gemcitabine 1000 mg/m
 <sup>2</sup> on days 1, 8, and 15 of a cycle, intravenous cisplatin 100 mg/m
 <sup>2</sup> on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1–5 (GEM-P) administered every 28 days is associated with 69% to 100% of pretreated patients with peripheral T-cell lymphoma achieving an objective response, and 19% to 50% achieving a complete response;
 <xref rid="bib14" ref-type="bibr">14</xref>, 
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref> a median progression-free survival of 12 months has been reported in the largest retrospective series.
 <xref rid="bib16" ref-type="bibr">
  <sup>16</sup>
 </xref>
</p>
